MA29268B1 - Comprimes presentant une dispersibilite amelioree de la substance medicamenteuse - Google Patents

Comprimes presentant une dispersibilite amelioree de la substance medicamenteuse

Info

Publication number
MA29268B1
MA29268B1 MA30164A MA30164A MA29268B1 MA 29268 B1 MA29268 B1 MA 29268B1 MA 30164 A MA30164 A MA 30164A MA 30164 A MA30164 A MA 30164A MA 29268 B1 MA29268 B1 MA 29268B1
Authority
MA
Morocco
Prior art keywords
tablets
improved dispersibility
vehicle
medicinal substance
spray granulation
Prior art date
Application number
MA30164A
Other languages
English (en)
Inventor
Nathalie Bernigal
Eric Garcia
Susanne Page
Joseph Tardio
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36406213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29268(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA29268B1 publication Critical patent/MA29268B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRÉSENTE INVENTION SE RAPPORTE À UN PROCÉDÉ PERMETTANT DE PRÉPARER DES COMPOSITIONS PHARMACEUTIQUES SE PRÉSENTANT SOUS FORME DE COMPRIMÉS ET DOTÉES D'UNE DISPERSIBILITÉ DE SUBSTANCE MÉDICAMENTEUSE AMÉLIORÉE. LEDIT PROCÉDÉ EST CARACTÉRISÉ EN CE QU'IL COMPREND LES ÉTAPES SUIVANTES : (A) PRÉPARATION D'UNE DISPERSION D'AU MOINS UNE SUBSTANCE MÉDICAMENTEUSE PHARMACEUTIQUEMENT ACTIVE ET D'AU MOINS UN TENSIO-ACTIF ET/OU UN LIANT DANS UN LIQUIDE ; (B) PRÉPARATION D'UN VÉHICULE, PAR LE MÉLANGE SEC D'UN OU PLUSIEURS EXCIPIENTS, DONT AU MOINS UN VÉHICULE POREUX ; ET (C) GRANULATION PAR PULVÉRISATION DE LA DISPERSION PRÉPARÉE À L'ÉTAPE (A) SUR LE VÉHICULE PRÉPARÉ À L'ÉTAPE (B), AFIN D'OBTENIR UN PRODUIT DE GRANULATION PAR PULVÉRISATION.
MA30164A 2005-02-25 2007-08-24 Comprimes presentant une dispersibilite amelioree de la substance medicamenteuse MA29268B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05101458 2005-02-25

Publications (1)

Publication Number Publication Date
MA29268B1 true MA29268B1 (fr) 2008-02-01

Family

ID=36406213

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30164A MA29268B1 (fr) 2005-02-25 2007-08-24 Comprimes presentant une dispersibilite amelioree de la substance medicamenteuse

Country Status (20)

Country Link
US (2) US20060193910A1 (fr)
EP (2) EP1855655A2 (fr)
JP (1) JP2008531509A (fr)
KR (1) KR20070094666A (fr)
CN (1) CN101128189A (fr)
AR (1) AR055561A1 (fr)
AU (1) AU2006218193A1 (fr)
BR (1) BRPI0606187A2 (fr)
CA (1) CA2598762A1 (fr)
CR (1) CR9292A (fr)
IL (1) IL185011A0 (fr)
MA (1) MA29268B1 (fr)
MX (1) MX2007009571A (fr)
NO (1) NO20074092L (fr)
NZ (1) NZ560232A (fr)
RU (1) RU2007129642A (fr)
TW (1) TW200640502A (fr)
UA (1) UA90708C2 (fr)
WO (1) WO2006089674A2 (fr)
ZA (1) ZA200706495B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20090196923A1 (en) * 2006-04-26 2009-08-06 Jayanta Kumar Mandal Controlled release formulation comprising anti-epileptic drugs
CN101820863A (zh) * 2007-10-10 2010-09-01 马林克罗特贝克公司 直接可压制的高功能性颗粒状微晶纤维素基赋形剂、其制备方法和用途
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
ES2397558T3 (es) * 2009-01-23 2013-03-07 F. Hoffmann-La Roche Ag Composición farmacéutica que comprende aleglitazar
CN106512010A (zh) 2009-11-18 2017-03-22 赫尔辛医疗股份公司 用于治疗中枢介导的恶心及呕吐的组合物及方法
EP2722045B1 (fr) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions pour traiter les nausées et vomissements à médiation centrale
CN102641302B (zh) * 2011-02-18 2016-01-20 上海张江中药现代制剂技术工程研究中心 一种提高中药提取物浸膏粉软化点的方法
RU2468789C1 (ru) * 2011-05-04 2012-12-10 Федеральное государственное бюджетное учреждение науки Иркутский институт химии им. А.Е. Фаворского Сибирского отделения Российской академии наук (ИрИХ СО РАН) Средство для профилактики и лечения атеросклероза
CN104784239B (zh) * 2015-04-28 2017-12-26 新乡医学院第一附属医院 一种快速溶出的珍菊降压片及其制备工艺
KR20170003414A (ko) * 2015-06-30 2017-01-09 (주)아모레퍼시픽 속붕해형 과립환 모발 세정용 조성물
WO2017003137A1 (fr) * 2015-06-30 2017-01-05 (주)아모레퍼시픽 Composition nettoyante granulaire à désintégration rapide pour les cheveux
PE20191239A1 (es) 2016-11-16 2019-09-16 Abide Therapeutics Inc Formas cristalinas de un inhibidor de magl
AU2017361254B2 (en) 2016-11-16 2021-09-23 H. Lundbeck A/S. Pharmaceutical formulations
CN109701441B (zh) * 2018-12-16 2021-04-09 桂林理工大学 一种卵磷脂选择性改性高岭石的制备方法及其应用
TWI728709B (zh) * 2020-02-19 2021-05-21 台灣森本生物科技開發股份有限公司 含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方
CN111548218A (zh) * 2020-04-27 2020-08-18 上海应用技术大学 一种通用型花肥速释片及其制备方法和应用
CN116602928A (zh) * 2023-06-30 2023-08-18 康普药业股份有限公司 一种甲苯磺酸艾多沙班组合物和制备方法
US12296050B2 (en) * 2023-10-05 2025-05-13 Mirum Pharmaceuticals, Inc. Pharmaceutical compositions comprising maralixibat and uses thereof
US12605388B2 (en) 2024-09-25 2026-04-21 Azurity Pharmaceuticals Ireland Limited Lamotrigine salts, co-crystals, and compositions
CN119857081B (zh) * 2025-01-16 2025-10-17 江苏亚邦爱普森药业有限公司 一种乌帕替尼缓释片及其制备方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20021701L (fi) * 1991-01-30 2002-09-24 Wellcome Found Veteen dispergoituvia tabletteja
EP1082959A1 (fr) 1991-09-20 2001-03-14 Glaxo Group Limited Utilisation des NK1-antagonistes pour le traitement de la depression
DK0782449T3 (da) * 1994-09-22 2003-08-04 Akzo Nobel Nv Fremgangsmåde til fremstilling af doseringsenheder ved vådgranulering
US6106865A (en) * 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
WO1998024438A1 (fr) 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Utilisation d'antagonistes du recepteur nk-1 dans le traitement des etats depressifs majeurs
AU736042B2 (en) 1996-12-02 2001-07-26 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
JP4367723B2 (ja) * 1997-08-25 2009-11-18 大正製薬株式会社 水難溶性成分を配合した固形剤
GB9825242D0 (en) 1998-11-19 1999-01-13 Cambridge Advanced Tech Genetically modified plants with altered starch
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
DK1394150T3 (da) 1999-02-24 2011-03-21 Hoffmann La Roche 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
WO2000050398A2 (fr) 1999-02-24 2000-08-31 F. Hoffmann-La Roche Ag Derives de pyridinyl et de phenyle
EP1157005B1 (fr) 1999-02-24 2004-10-20 F. Hoffmann-La Roche Ag Derives de 3-phenylpyridine et utilisation de ces derniers comme antagonistes de recepteur nk-1
JP3702182B2 (ja) 1999-03-06 2005-10-05 ロシュ ダイアグノスティックス ゲーエムベーハー ピロバクルム・イスランジカム（Ｐｙｒｏｂａｃｕｌｕｍｉｓｌａｎｄｉｃｕｍ）由来のＤＮＡポリメラーゼ
JO2308B1 (en) 1999-05-31 2005-09-12 اف. هوفمان- لاروش أيه جي‏ Derivatives of phenylpyrmidine
TW550258B (en) 1999-05-31 2003-09-01 Hoffmann La Roche 4-phenyl-pyrimidine derivatives
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
US6303790B1 (en) 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
EP1103545B1 (fr) 1999-11-29 2003-11-05 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluorométhyl-phényl)-N-méthyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
US6452001B2 (en) 2000-05-25 2002-09-17 Hoffmann-La Roche Inc. Diazapane derivatives useful as antagonists of neurokinin 1 receptor and methods for their formation
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
CN1178917C (zh) 2000-07-14 2004-12-08 弗·哈夫曼-拉罗切有限公司 作为nk1受体拮抗剂前药的4-苯基-吡啶衍生物的n-氧化物
TWI287003B (en) 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
YU39503A (sh) 2000-11-22 2006-05-25 F. Hoffmann-La Roche Ag. Derivati pirimidina
AU2002216085B8 (en) 2000-12-14 2006-03-02 F. Hoffmann-La Roche Ag Self Emulsifying Lipid Matrix (SELM)
US6642226B2 (en) 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
US6531597B2 (en) 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
MXPA03009720A (es) 2001-04-23 2004-01-29 Hoffmann La Roche USO DE ANTAGONISTAS DEL RECEPTOR DE NK-1 PARA TRATAMIENTO O PREVENCIoN DE HIPERPLASIA PROSTATICA BENIGNA.
EP1390372B1 (fr) 2001-05-14 2008-07-16 F. Hoffmann-La Roche Ag Derives de 1-oxa-3,9-diaza-spiro 5,5 undecan-2-ones et leur utilisation comme antagoniste du recepteur de neurikinie
US20030083345A1 (en) 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
US6667327B2 (en) 2002-02-04 2003-12-23 Hoffmann-La Roche Inc. Pyridine amido derivatives
US6660736B2 (en) 2002-03-27 2003-12-09 Hoffmann-La Roche Inc. Phthalimido derivatives and a process for their preparation
HRP20040952A2 (en) 2002-04-26 2005-06-30 F. Hoffmann - La Roche Ag Isoquinoline derivatives
SI1511718T1 (sl) 2002-05-29 2009-08-31 Hoffmann La Roche Derivati n-acilaminobenzena kot selektivni inhibitorji monoaminske oksidaze b
US6951884B2 (en) 2002-06-12 2005-10-04 Hoffmann-La Roche Inc. Fluorobenzamides and uses thereof
KR20030095600A (ko) * 2002-06-12 2003-12-24 환인제약 주식회사 펠로디핀을 포함하는 제어방출형 조성물 및 그 제조방법
US6900354B2 (en) 2002-07-15 2005-05-31 Hoffman-La Roche Inc. 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
US6846832B2 (en) 2002-08-07 2005-01-25 Hoffman-La Roche Inc. 2,3-dihydro-isoindol-1-one derivatives
TWI286132B (en) 2002-09-20 2007-09-01 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
JP2006056781A (ja) * 2002-11-15 2006-03-02 Bioserentack Co Ltd 界面活性剤を含む固形化製剤
PL377474A1 (pl) 2002-12-13 2006-02-06 F. Hoffmann-La Roche Ag Pochodne 3H-chinazolin-4-onu
PL378404A1 (pl) 2003-01-31 2006-04-03 F. Hoffmann-La Roche Ag Nowa odmiana krystaliczna 2-(3,5-bis-trifluorometylofenylo)-N-[6-(1,1-diokso-1<$Elambda>6 -tiomorfolin-4-ylo)-4-(4-fluoro-2-metylofenylo)pirydyn-3-ylo]-N-metyloizobutyroamidu
FR2851918B1 (fr) * 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics

Also Published As

Publication number Publication date
CN101128189A (zh) 2008-02-20
BRPI0606187A2 (pt) 2009-06-09
KR20070094666A (ko) 2007-09-20
WO2006089674A3 (fr) 2007-02-08
NZ560232A (en) 2010-11-26
RU2007129642A (ru) 2009-03-27
JP2008531509A (ja) 2008-08-14
EP2281556A1 (fr) 2011-02-09
US20090304795A1 (en) 2009-12-10
ZA200706495B (en) 2008-10-29
NO20074092L (no) 2007-09-04
AR055561A1 (es) 2007-08-22
EP1855655A2 (fr) 2007-11-21
TW200640502A (en) 2006-12-01
IL185011A0 (en) 2007-12-03
US20060193910A1 (en) 2006-08-31
CR9292A (es) 2010-04-21
WO2006089674A2 (fr) 2006-08-31
UA90708C2 (ru) 2010-05-25
AU2006218193A1 (en) 2006-08-31
MX2007009571A (es) 2007-09-21
CA2598762A1 (fr) 2006-08-31

Similar Documents

Publication Publication Date Title
CA2366027C (fr) Comprime orodispersible presentant une faible friabilite et son procede de preparation
KR101665001B1 (ko) ２­옥소­１­피롤리딘 유도체를 포함하는 약학적 조성물
KR101640164B1 (ko) ２­옥소­１­피롤리딘 유도체를 포함하는 약학적 조성물
NO20074092L (no) Tabletter for forbedret legemiddel dispersibilitet
FR2460667A1 (fr) Composition pharmaceutique a liberation prolongee a base d&#39;une substance medicamenteuse solide
JP6103111B1 (ja) 経口医薬組成物及び該組成物からなる粒子状製剤の製造方法
CA2534997A1 (fr) Methodes d&#39;administration de l&#39;aripiprazole
WO2008037557A3 (fr) Médicaments anti-inflammatoires non stéroïdiens solubilisés
EP1985288B1 (fr) Préparation solide orale et son procédé de fabrication
TWI492747B (zh) 壓縮製劑
Monti et al. Poloxamer 407 microspheres for orotransmucosal drug delivery. Part II: In vitro/in vivo evaluation
EP0290299B1 (fr) Forme galénique à base d&#39;extrait sec de plantes
EP1646373B1 (fr) Composition pharmaceutique orodispersible d&#39;un compose antithrombotique
WO2007086911A3 (fr) Formulations nanoparticulaires stables
RU2005131494A (ru) Твердая лекарственная форма, содержащая десмопрессин
CN113365611A (zh) 制备包含奈福泮和对乙酰氨基酚的药物组合物的方法和由该方法获得的药物组合物
EP3139905B1 (fr) Co-granules de gomme de xanthane et de gomme d&#39;acacia
KR100546047B1 (ko) 디히드로피리딘계 화합물의 서방출성 제제 및 그 제조방법
CA3106495C (fr) Composition pharmaceutique sous la forme d&#39;un comprime a croquer de diosmine ou d&#39;une fraction flavonoique
FR2785191A1 (fr) Utilisation de gommes xanthanes pour la preparation de compositions pharmaceutiques
JP5977192B2 (ja) 経口固形製剤及びその製造方法
Narode et al. FORMULATION AND INVIVO EVALUATION OF METHOTREXATE HOT MELT EXTRUDES USING KOLLIDON VA 64 & PEG 1500
WO2008089773A1 (fr) Formulation d&#39;une matrice a desintegration rapide
TH59782A3 (th) สารผสมของกาแลนแทมีนชนิดปลดปล่อยที่มีการควบคุม
TH74101A (th) รูปยาตามขนาดยาทางเภสัชกรรมที่ปลดปล่อยเป็นช่วงเวลานาน